RU2010136047A - КАТИОННЫЕ siPНК, СИНТЕЗ И ПРИМЕНЕНИЕ В РНК-ИНТЕРФЕРЕНЦИИ - Google Patents

КАТИОННЫЕ siPНК, СИНТЕЗ И ПРИМЕНЕНИЕ В РНК-ИНТЕРФЕРЕНЦИИ Download PDF

Info

Publication number
RU2010136047A
RU2010136047A RU2010136047/10A RU2010136047A RU2010136047A RU 2010136047 A RU2010136047 A RU 2010136047A RU 2010136047/10 A RU2010136047/10 A RU 2010136047/10A RU 2010136047 A RU2010136047 A RU 2010136047A RU 2010136047 A RU2010136047 A RU 2010136047A
Authority
RU
Russia
Prior art keywords
cationic
formula
sirna
charges
sirna according
Prior art date
Application number
RU2010136047/10A
Other languages
English (en)
Russian (ru)
Inventor
Жан-Поль БЕР (FR)
Жан-Поль БЕР
Мицухару КОТЕРА (FR)
Мицухару КОТЕРА
Надеж ПФЭНДЕР (FR)
Надеж ПФЭНДЕР
Жан-Серж РЕМИ (FR)
Жан-Серж РЕМИ
Original Assignee
Сантр Насьональ де ля Решерш Сьянтифик (FR)
Сантр Насьональ Де Ля Решерш Сьянтифик
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантр Насьональ де ля Решерш Сьянтифик (FR), Сантр Насьональ Де Ля Решерш Сьянтифик filed Critical Сантр Насьональ де ля Решерш Сьянтифик (FR)
Publication of RU2010136047A publication Critical patent/RU2010136047A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2010136047/10A 2008-01-30 2009-01-30 КАТИОННЫЕ siPНК, СИНТЕЗ И ПРИМЕНЕНИЕ В РНК-ИНТЕРФЕРЕНЦИИ RU2010136047A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR08/00492 2008-01-30
FR0800492A FR2926818B1 (fr) 2008-01-30 2008-01-30 siRNA CATIONIQUES, SYNTHESE ET UTILISATION POUR L'ARN INTERFERENCE

Publications (1)

Publication Number Publication Date
RU2010136047A true RU2010136047A (ru) 2012-03-10

Family

ID=39683957

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010136047/10A RU2010136047A (ru) 2008-01-30 2009-01-30 КАТИОННЫЕ siPНК, СИНТЕЗ И ПРИМЕНЕНИЕ В РНК-ИНТЕРФЕРЕНЦИИ

Country Status (13)

Country Link
US (1) US10927371B2 (https=)
EP (1) EP2250267B1 (https=)
JP (1) JP2011511776A (https=)
KR (1) KR20100120293A (https=)
CN (1) CN101960009A (https=)
AU (1) AU2009208646A1 (https=)
BR (1) BRPI0907494A2 (https=)
CA (1) CA2713075A1 (https=)
FR (1) FR2926818B1 (https=)
IL (1) IL207290A0 (https=)
NZ (1) NZ587117A (https=)
RU (1) RU2010136047A (https=)
WO (1) WO2009095887A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ569138A (en) 2005-12-15 2012-06-29 Centre Nat Rech Scient Cationic oligonucleotides automated methods for preparing same and their uses
EP3027223A1 (en) * 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
EP3265567B1 (en) 2015-03-02 2020-07-29 Conagen Inc. Regulatory elements from labyrinthulomycetes microorganisms
US10457970B2 (en) 2016-11-01 2019-10-29 Conagen Inc. Expression of modified glycoproteins and glycopeptides
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
CN106498072B (zh) * 2016-11-24 2019-09-10 青岛千卓分子生物科技有限公司 一种液态产品中外源dna内标物的保护方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
EP1013770A1 (en) 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
US20040019008A1 (en) 2002-05-28 2004-01-29 Lewis David L. Compositions and processes using siRNA, amphipathic compounds and polycations
JP2004137143A (ja) 2002-08-21 2004-05-13 Fuji Photo Film Co Ltd 有機変性層状珪酸塩及びその組成物
EP1585756B1 (en) * 2002-11-26 2010-04-21 University of Massachusetts Delivery of sirnas
EP1638919B1 (en) * 2003-06-18 2012-09-26 Biolab Ltd. Sphingolipids polyalkylamines conjugates
EP1709195B1 (en) * 2003-12-19 2014-01-22 Novartis Vaccines and Diagnostics, Inc. Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
US20060073505A1 (en) * 2004-09-21 2006-04-06 Isis Pharmaceuticals, Inc. Oligomeric compounds effecting drosha-mediated cleavage
WO2006052854A2 (en) * 2004-11-04 2006-05-18 Raul Andino Syntheses of polyamine conjugates of small interfering rnas (si-rnas) and conjugates formed thereby
CN101060849A (zh) * 2004-11-17 2007-10-24 巴尔的摩马里兰大学 作为有效的siRNA载体的高分支HK肽
NZ569138A (en) * 2005-12-15 2012-06-29 Centre Nat Rech Scient Cationic oligonucleotides automated methods for preparing same and their uses
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
JP2009534342A (ja) * 2006-04-20 2009-09-24 サイレンス・セラピューティクス・アーゲー 血管内皮に特異的に送達するためのリポプレックス処方剤

Also Published As

Publication number Publication date
IL207290A0 (en) 2010-12-30
FR2926818B1 (fr) 2012-04-06
EP2250267A1 (fr) 2010-11-17
BRPI0907494A2 (pt) 2019-09-24
FR2926818A1 (fr) 2009-07-31
CN101960009A (zh) 2011-01-26
EP2250267B1 (fr) 2016-09-14
WO2009095887A1 (fr) 2009-08-06
NZ587117A (en) 2012-09-28
JP2011511776A (ja) 2011-04-14
AU2009208646A1 (en) 2009-08-06
US10927371B2 (en) 2021-02-23
KR20100120293A (ko) 2010-11-15
CA2713075A1 (fr) 2009-08-06
US20110118331A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
RU2010136047A (ru) КАТИОННЫЕ siPНК, СИНТЕЗ И ПРИМЕНЕНИЕ В РНК-ИНТЕРФЕРЕНЦИИ
WO2007069092A3 (en) Cationic oligonucleotides, automated methods for preparing same and their uses
Micklefield Backbone modification of nucleic acids: synthesis, structure and therapeutic applications
AU2009322290B2 (en) Una oligomer structures for therapeutic agents
US8466120B2 (en) Oligomeric compounds and compositions for use in modulation of pri-miRNAs
KR20230058624A (ko) Adar 의존성 편집 조성물 및 그의 사용 방법
JP2013510561A5 (https=)
SI2902406T1 (en) Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US20120115228A1 (en) Oligomeric compounds and compositions for the use in modulation of micrornas
RU2010120715A (ru) Модифицированная липидом двухцепочечная рнк, обладающая сильным эффектом рнк-интерференции
JP2007500018A5 (https=)
JP2017079776A5 (https=)
JP2010528041A5 (https=)
WO2010145778A1 (en) MODIFIED siNA
CN104955950A (zh) 具有改善的脱靶特征谱的寡核苷酸
JP2008283975A5 (https=)
NZ599237A (en) Sirna compounds comprising terminal substitutions
IL316212A (en) Modulators of HSD17B13 expression
JP2020505032A5 (https=)
JP2017528441A5 (https=)
Fabbri et al. miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs
JP2008500817A5 (ja) Ｄｎａウイルスのマイクロｒｎａ及びそれを阻害する医薬品
US10844376B2 (en) Structurally-enhanced miRNA inhibitor S-TuD
JP2006067889A5 (https=)
JP2024528252A (ja) 核酸医薬の徐放性能の強化方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130801